During the past decade, Rigshospitalet; Ny Medicin til Børn med Kræft conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Rigshospitalet; Ny Medicin til Børn med Kræft" are "ALK Fusion-positive Solid or CNS Tumors" (1 trials) and "Mature B-Cell Non-Hodgkin Lymphoma" (1 trials). Many other conditions were trialed in "Rigshospitalet; Ny Medicin til Børn med Kræft" in a lesser frequency.

Most popular intervention types in "Rigshospitalet; Ny Medicin til Børn med Kræft" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Alectinib" (1 trials), "Carboplatin" (1 trials), "Etoposide" (1 trials), "Glofitamab" (1 trials) and "Ifosfamide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rigshospitalet; Ny Medicin til Børn med Kræft" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Rigshospitalet; Ny Medicin til Børn med Kræft". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Rigshospitalet; Ny Medicin til Børn med Kræft, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Rigshospitalet; Ny Medicin til Børn med Kræft, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".